Skip to main content
AmigoFish

Breaking Drug News: Combination GLP-1s, Treatment for Kids, and Lp(a)

From Fat Science · · 47 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

What do new drug reports really mean for your treatment?

Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues.

KEY TAKEAWAYS

- Understanding the difference between efficacy estimand and treatment policy estimand.

- Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes.

- Semaglutide's effectiveness in children and its implications.

NOTABLE QUOTE

"Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper

LINKS & RESOURCES

Learn more about Diabesity Foundations: learn.diabesityinstitute.org (https://diabesityinstitute.org)

Podcast Home:fatsciencepodcast.com (https://fatsciencepodcast.com/)

Cooper Center for Metabolism:coopermetabolic.com (https://coopermetabolic.com/)

Diabesity Institute: diabesityinstitute.org (https://diabesityinstitute.org)

Resources from Dr. Cooper:coopermetabolic.com/resources (https://coopermetabolic.com/resources)

Join Our Community:patreon.com/cw/FatSciencePodcast (https://patreon.com/cw/FatSciencePodcast)

Submit Your Question: questions@fatsciencepodcast.com (http://docs.google.com/questions@fatsciencepodcast.com) or dr.c@fatsciencepodcast.com (http://docs.google.com/dr.c@fatsciencepodcast.com)

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Back to Fat Science · Report a problem